Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-11-14 Major Shareholding Noti…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. This document specifically details the shareholding status of Cha Kwang-yul and his special related parties in the company 'Cha Biotech'. It includes information on share ownership, changes in shareholding, and details of collateral contracts (stock-backed loans). This type of filing is classified as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-11-14 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '차바이오텍' (Chabiotech Co., Ltd.) covering the period from January 1, 2022, to September 30, 2022. It contains detailed financial data, business descriptions, and management information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-11 Korean
투자판단관련주요경영사항(조기난소부전(POI) 환자 대상 탯줄유래 줄기세포 치료의 제1상 임상시험 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 1 clinical trial for a stem cell treatment. It details the regulatory approval from the Ministry of Food and Drug Safety (MFDS), the trial design, and the clinical objectives. Since it is a specific regulatory disclosure of a material event (clinical trial approval) that does not fit into the other specialized categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2022-11-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of a major shareholder (Cha Kwang-yul) and their special related parties in the company 'Cha Biotech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-10-31 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status of a major shareholder (Cha Kwang-yul) and his special related parties in the company 'Cha Biotech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-10-06 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the shareholding status, changes in ownership (including '장내매수' or open market purchases), and the relationship between the reporter (Cha Kwang-yul) and special related parties. This document type is specifically designed to notify the market and regulators of significant changes in share ownership, which falls under the 'Major Shareholding Notification' category.
2022-09-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.